EKF Diagnostics Holdings plc is a global manufacturer of medical diagnostic products and services headquartered in Cardiff, UK and with facilities in Europe and the USA.
EKF sells through a network of distributors around the world; however our German and American offices also sell directly into hospital laboratories, GP surgeries as well as into universities and sports organisations.
EKF Diagnostics is listed on AIM on the London Stock Exchange. The business has four key divisions, shown below, each of which has it's own unique set of attributes.
EKF Point of Care (POC) analyzers are designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide fast and accurate results at an affordable price.
EKF's Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories. It also supplies benchtop automated and semi-automated analysers, as well as centrifuges and some rapid test kits.
EKF Life Sciences specializes in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. EKF Life Science facilities are based in two locations in Indiana, USA.
EKF Contract Manufacturing provides specialized services to the diagnostics and healthcare industries for the production of custom kits. With facilities in the US, UK and Germany EKF is able to provide bulk formulation, dispensing and kitting services, as well as provide advice and guidance on Regulatory requirements. EKF's end-to-end service also includes sourcing, print and compilation of packaging, IFUs and labelling.
All EKF's facilities are accredited by the international standards agencies that oversee the design and manufacture of medical devices. EKF-diagnostic GmbH and Stanbio Laboratory are both FDA registered facilities, whilst Stanbio is also accredited by the Canadian Medical Devices Conformity Assessment Scheme (CMDCAS).
EKF is a global company with offices in the UK, Germany, USA, Russia and China and counts with a network of more than 200 distributors covering every country.
We keep our network up-to-date with our products with constant training and attending to global events like Medica, MedLab or AACC across countries.
EKF Diagnostics is a global medical manufacturer of Point-of-Care and Central Laboratory devices and tests including hemoglobin tests, HbA1c tests, glucose and lactate tests.
The UK office is headquarters to our finance and marketing teams and a newly opened lab facility. Our German office is home to EKF's manufacturing, R&D and Regulatory Affairs departments for our Point of Care range. EKF also has manufacturing sites in San Antonio and Indiana in the USA.
There are currently no vacancies available.
See our vacancies at EKF-diagnostic GmbH which is based near Magdeburg, in Germany.
See our vacancies for the US.
1990
EKF Industrie-Elektronik established. This company would go on to develop Hemo Control and Biosen.
2000
EKF Industrie-Elektronik renamed EKF-diagnostic GmbH.
2004
EKF-diagnostic sales GmbH and EKF-diagnostic Russia founded.
2006
EKF-diagnostyka Poland founded.
2010
EKF GmbH acquired by IBL plc and is listed on London Stock Exchange as EKF Diagnostics Holdings plc.
Quotient Diagnostics Ltd and Argutus Medical Ltd subsequently acquired to expand the Diabetes Care portfolio with the Quo-Lab and Quo-Test HbA1c analysers along with the predictive kidney biomarker sTNFR1.
2011
Stanbio Laboratory acquired by EKF Diagnostics Holdings plc adding a Clinical Chemistry portfolio of more than a 80 reagents, controls, calibrators, and standards, as well as a enzyme manufacturing plant in Elkhart now known as EKF Life Sciences.
2014
DiaSpect Medical AB and Separation Technology acquired to supplement EKF's hemoglobin range with DiaSpect and UltraCrit.
2016
Manufacturing consolidated into two sites - Barleben, near Magdeburg in Germany and Boerne, near San Antonio in Texas.
2018
EKF Diagnostics announces record revenues and profitability, as well as the successful floatation of spin-out, Renalytix AI, on AIM.
2020
Production starts in the USA, UK and Germany of PrimeStore MTM - a transport media for samples that may contain an infection disease such as COVID-19, influenza or TB.
2021
Trellus Health, a joint venture with Mount Sinai, admitted to AIM.
Acquisition of ADL Health, a CLIA certified lab in San Antonio, Texas which specialises in quick-turnaround COVID-19 testing for companies and individuals.
EKF Diagnostics Holdings plc is listed on the London Stock Exchange. For Investor Announcements (RNS), Company Information and background to the Board of Directors and Advisors visit the Investors section of this website.
Copyright © 2023 | Powered by Intergage
Please note: Not all products are available in all countries. Please check availability.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.